Ten-year review of invasive pneumococcal diseases in children and adults from uruguay: Clinical spectrum, serotypes, and antimicrobial resistance  by Hortal, María et al.
Original Report 
Ten-Year Review of Invasive Pneumococcal Diseases 
in Children and Adults from Uruguay: Clinical 
Spectrum, Serotypes, and Antimicrobial Resistance 
Maria Hortal, MD;* Teresa Camou, MB&* Rosario Palacio, MD;* 
Hugo Dibarboure, MD;+ and Albert0 Garcia, MD* 
ABSTRACT 
Objectives: Since 1987, the Reference Laboratory of the Min- 
istry of Health of Uruguay has been monitoring infections due 
to Streptococcus pneumoniae in patients under 5 years of age, 
in those between 5 to 14 years of age, and in adults. The 
purpose of the present study was to retrospectively analyze a 
1 O-year collection of invasive S. pneumoniae isolates from chil- 
dren 5 to 14 years of age and adults. 
Methods: The Reference Children’s Hospital, Pasteur Hospital, 
and two private hospitals in Montevideo as well as four hospi- 
tals located in other representative areas of the country par- 
ticipated in the pneumococcal surveillance program. Based on 
the information available at the Microbiology Department of the 
Central Public Health Laboratory (demographic data, date and 
site of isolate, and clinical diagnosis), all patients with an inva- 
sive pneumococcal disease were recorded. Pneumonia was 
clinically and radiologically diagnosed and etiology was 
assessed by isolation of S. pneumoniae from blood or pleural 
fluid. All specimens were collected at the Emergency Service. 
Capsular serotyping and antimicrobial susceptibilities were 
determined for each isolate. 
Results: During the IO-year period, 228 invasive S. pneumo- 
niae were identified and included in the study (blood, n = 129; 
cerebrospinal fluid [CSF], n = 73; pleural fluid, n = 20; peri- 
toneal fluid, n = 3; synovial fluid, n = 1; pericardic fluid, n = 1; 
abscess, n = 1). The most frequent clinical presentations were 
pneumonia (n = 71) and meningitis (n = 69). Thirty-five adults 
had an underlying condition including, four with malignancies, 
four with lupus, two with human immunodeficiency virus (HIV)- 
infected, and two patients in hemodialysis among others, Eigh- 
teen of the 228 patients died (7.9% fatality rate), but only four 
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of these had an underlying condition. Eleven fatal cases were 
attributable to meningitis (2 children, 9 and 11 years old; 
9 adults, mean age, 59 y). Four patients with pneumonia and 
three with sepsis died, including a splenectomized woman. 
Nine different capsular serotypes (1, 5, 7, 9, 12, 15, 19A, 20, 
and 23A) were identified among the 18 fatal cases. Resistance 
to penicillin, generally combined with trimethoprim-sulfameth- 
oxazole, fluctuated annually, not surpassing 10%. 
Conclusions: The study results indicated that 96% of the 
serotypes involved in severe pneumococcal diseases were 
included in the 23-valent vaccine and that S. pneumoniae resis- 
tance to penicillin was moderate. 
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The Expanded Program on Immunization (EPI) and sup- 
plementary vaccines used regularly and consistently by 
the health authorities initiative in Uruguay have reduced 
and almost eliminated several infectious diseases includ- 
ing polio, mumps, measles, rubella, and Haemophilus 
infuenzae type B invasive infections.* However, there 
still are infections caused by microorganisms capable of 
producing high morbidity and mortality, hospitalizations, 
and social costsThis is the situation with infections 
caused by Streptococcus pneumoniae, which has some 
peculiar characteristics? Although it affects people at any 
age, the severity and frequency are greater in extreme 
ages of life.The prevention of these infections in adults 
is one of the concerns faced by Public Health.3*4 The 
increasing resistance to B-lactam antibiotics and the phe- 
nomenon of multiresistance, observed among pneumo- 
cocci worldwide, are additional causes of concern.This 
resistance is difficult to overcome; it increases costs of 
medical care and interferes with the outcome of the dis- 
ease.5 These factors emphasize the need of resources for 
the specific prevention of invasive pneumococcal infec- 
tions in Uruguay, as in the rest of the world. 
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Since 1983, a 23-valent pneumococcal polysaccha- 
ride vaccine has been available, containing the serotypes 
mOSt frequently isolated in cerebrospinal fluid (CSF), 
blood, and pleural and synovial fluids from patients from 
various countries,6 This vaccine gives immunocompetent 
individuals a reasonable degree of protection. Although 
the immunity conferred averages 80%, many factors lead 
to its underutilization.7-10 Revaccination after 3 to 5 years 
is recommended for some at risk groups, such as the 
elderly. i1 The capsular polysaccharide vaccine, which 
comprises Tcell-independent antigens, is poorly immune- 
genie in Infants whose immune systems are immature. 
Therefore this vaccine is not recommended for use in 
children younger than 2 years of age.‘* 
The present goal is to prepare a 7- to ll-valent pro- 
tein-conjugated vaccine containing the most frequently 
occurring pediatric pneumococcal types that will pre- 
vent the majority of invasive infectionsThese vaccines 
induce immunologic responses during the first months 
of life and, at the same time, provide an effective immune 
logic memory.13 This type of vaccine also could be use- 
ful for protection in immunocompromised people or in 
elderly people with a diminished immunologic re- 
sponse. ‘* Frequency and serotype distribution vary 
according to the age of the patient, and because there is 
geographic variability of pneumococcal serotypes that 
cause invasive infections, the potential benefit of such 
vaccines should be determined for each region. Conse- 
quently, for an adequate formulation of these vaccines 
and for their rational use, it is necessary to know which 
capsular types are locally predominant in systemic infec- 
tions of children and adults. 
Since 1987, the Reference Laboratory of the Ministry 
of Health has been monitoring these infections, to char- 
acterize the Spneumoniue isolated from patients under 
5 years of age, those between 5 and 14 years of age, and 
from adult patients. I5 The purpose of the present study 
was to retrospectively analyze a lo-year collection of inva- 
sive S.pneumoniue isolates from children, aged 5 to 14 
years, and adults. 
MATERIALS AND METHODS 
Study Population 
The population of Uruguay is 3,146,200 million inhabi- 
tants (National Census, 1996) of whom approximately 
50% reside in the metropolitan region of Montevideo. In 
1996, infant mortality was 17.5 per 1000 live births. In 
Uruguay, 35% of the total population receives health care 
from the government health system. The EPI is coordi- 
nated and defined at the national level by the Ministry of 
Health. The Reference Children’s Hospital, Pasteur HOS- 
pital, and two private hospitals in Montevideo as well as 
four hospitals located in other representative areas of the 
country participated in the pneumococal surveillance 
program. 
To assess the occurrence of invasive pneumococcal 
disease among children older than 5 years and adults, 10 
years of laboratory data were reviewed (January 1987 
to December 1997). Based on the information available 
at the Microbiology Department of the Central Public 
Health Laboratory (demographic data, date and site of 
isolate, and clinical diagnosis), all patients with an inva- 
sive pneumococcal disease were recorded. Some chil- 
dren and adults were outpatients, but most of them were 
hospitalized with community-acquired infections. Pneu- 
monia was clinically and radiologically diagnosed and 
etiology was assessed by isolation of S. pneumoniae 
from blood or pleural fluidAll specimens were collected 
at the Emergency Service. Only one isolate per patient 
was considered 
Microbiologic Methods 
Conventional bacterial methods were used for S. pneu- 
moniae identification (colonial morphology, optochin 
test, bile solubility).According to the National Committee 
for Clinical Laboratory Standards (NCCLS) criteria, sus- 
ceptibility to seven antimicrobial agents was assayed by 
disk diffusion technique (oxacillin, erythromycin, chlor- 
amphenicol, trimethoprim-sulfamethoxazole [TMP-SMZ] , 
tetracycline, rifampin, and vancomycin). 
In strains resistant to oxacillin (119 mm), the mini- 
mal inhibitory concentration (MIC) was determined by 
broth microdilution or E-test (AB Biodisk, Solna, Sweden) 
for penicillin, cefotaxime, and ceftriaxone. Isolates with 
MIC values to penicillin of less than 0.1 mg/L were con- 
sidered susceptible; MICs 0.1 to 1 .O mg/L, intermediately 
resistant, and those with MIC values above 1 .O mg/L were 
defined as resistant, according to the guidelines of the 
NCCLS. The same guidelines applied when other anti- 
biotics were considered. Multiresistance was defined as 
being resistant to three or more antimicrobial classes. 
Capsular serotyping was performed in Uruguay, based 
on the Quellung technique, according to a chessboard 
scheme using 12 pools of antisera and additional factors 
produced by the Statens Seruminstitut (SSI) of Copen- 
hagen, Denmark. Periodically, isolates were sent to the 
SSI, for quality control and factoring of the least frequent 
types. 
RESULTS 
During the lO-year period, 228 invasive S. pneumoniue 
were identified and Included in the study (blood, n = 129; 
CSE n = 73; pleural fluid, n = 20; peritoneal fluid, n = 3; 
synovial fluid, n = 1; pericardial fluid, n = 1; abscess, 
n = l).Table 1 lists the different pathologies according to 
age groups in those patients whose age was recorded.The 
most frequent clinical presentations were pneumonia 
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Table 1. Age Distribution of Invasive Pneumococcal infections According to Clinical Diagnosis 
Clinical Diagnosis 5-14 15-24 
n = 171 (700%) n = 28 (%) n = 7 (%) 
Meningitis n = 69 (40%) 8 (2% 3 (43) 
Pneumonia n = 71 (42%) 20 (71) 3 (43) 
Other+ n = 31 (18%) 1 (14) 
*Age not recorded for 57 patients; ‘bacteremia or sepsis, peritonitis, cellulitis, etc. 
25-44 45-64 >65 
n=31(%) n=47 (%) n = 64 @) 
18 (58) 21 (51) 19 (30) 
6 (19) 13 (32) 29 (45) 
7 (23) 7 (17) 16 (25) 
(n = 71) and meningitis (n = 69). Clinical presentations 
varied depending on age. In elderly people pneumonia 
predominated, whereas meningitis was most frequently 
observed in patients between 25 and 65 years of age. 
Other pathologies, including sepsis or bacteremia (n = 
22), peritonitis (n = 2), abscess (n = 2), and others (n = 
5), were not recorded among children. 
Table 2 shows the serotype distribution of the pre- 
dominant pathologies and, in order of frequency, the I2 
most frequently noted serotypes, which represented 
81.1% of the S. pneumoniae associated with systemic 
Thirty-five adults had an underlying condition, includ- 
ing four with malignancies, four with lupus, two with 
infections. Seven of the predominant capsular serotypes 
human immunodeficiency virus (HIV) infection, and two 
persisted over the observation period and were respon- 
patients in hemodialysis, among others. Eighteen of the 
228 patients died (7.9% fatality rate), but only four of 
these had an underlying condition. Eleven fatal cases were 
sible for 71% of pneumonia cases and 50.6% of menin- 
due to meningitis (2 children, 9 and 11 years old; 9 adults, 
mean age, 59 y). Four patients with pneumonia and three 
with sepsis died, including a splenectomized woman. 
Nine different capsular serotypes (1,5,7,9, 12, 15, 19A, 
20, and 23A) were identified among the 18 fatal cases. 
gitis. Serotype 5 and 14 were more frequently associated 
with pneumonia, whereas group-type 12-l 2F predomi- 
nated in meningitis. Only 3.9% of serotypes identified 
were not included in the 23-valent vaccine, and serotypes 
2 and 33E included in this vaccine, were not diagnosed 
during the surveillance period. Group-types 11, 18-18E 
and 19 only became associated with systemic infections 
after 1994. 
Table 3 presents the occurrence of antimicrobial resis- 
tance by years. Resistance to penicillin, generally combined 
with TMP-SMZ, fluctuated annually, not surpassing 10%. 
Of 28 strains resistant only to TMP-SMZ, 10 were 
already present in the earlier years of the study 
(1987-1993).-o of them belonged to serotype 14 and 
16 (61%) belonged to the following serotypes: 11 (n = 6), 
1 (n = 5), and 5 (n = 5). Only two multiresistant strains 
were recognized (serotypes 11 and 23F).All the isolates 
The 20 isolates resistant to oxacillin showed MICs 
between 0.1 and 4.0 mg/L (10 intermediate and 10 resis- 
were susceptible to vancomycin and rifampin. 
tant). Of those isolates, eight had MIC values of 1 .O mg/L 
for cefotaxime and ceftriaxone.The majority of the resis- 
tant isolates belonged to serotype 14 (17/20), but none 
of the isolates from the fatal cases were resistant to 
penicillin. 
Table 2. Serotype Distribution of Invasive Pneumococcal Isolates According to Clinical Diagnosis 
Clinical Diagnosis 
Pneumonia Meningitis 
Serotype Group n=97 n = 79 
5 18 3 1 13 6 
7/7F 13 7 
14 15 4 
12/l 2F 2 11 
3 6 4 
9N 4 5 
18/18F 3 4 
8 3 3 
6N6B 5 2 
11 2 
1 19F 2 4 
Other 
Included in 23V 10 20 Not included in 23V 1 
5 
*Bacteremia or sepsis, peritonitis, cellulitis, etc. 23V = 23-valent vaccine. 
Other* No Data Total Cumulative 
n = 35 n= 77 n = 228 (100%) Percentage 
5 3 29 (12.7) 12.7 
5 4 28 (12.3) 25.0 
3 3 26 (11.4) 36.4 
2 1 22 (9.7) 46.1 
4 1 18 (7.9) 54.0 
0 2 12 (5.3) 59.3 
1 1 11 (4.8) 64.1 
3 1 11 (4.8) 68.9 
3 0 9 (3.9) 72.8 
0 0 7 (3.1) 75.9 
3 0 6 (2.6) 78.5 
0 0 6 (2.6) 81.1 
3 1 34 (15.0) 96.1 
3 0 9 (3.9) 100.0 
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Table 3. Susceptibility to Antibiotics of Invasive Pneumococcal Isolates by Years 
Number of Isolates Resistant to indicated Drugs 
Number of Susceptible Oxacillin- Oxacillin- TMP-SMZ- 
Isolates Isolates TMP-SMZ TMP-SMZ 
Year 
Tetracycline Erythromycin 
n=228 n = 7 71 (75%) 
Erythromycin Multiresistant 
n = 28 n = 79 (8%) n=5 n=l n=l n=2 
1987-90 14 9 (64) 4 (29) 1 (7) - - - - 
1991-93 25 18 (72) 6 (24) 1 (4) 
0 0 0 
94 5 35 (64) 9 16) 5 (9) Y(7) 1 (4 0 1 
1995 54 45 (83) 
(2) 
3 (6) 5 (9) 0 0 0 1 
1996 43 35 (81) 
(2) 
4 (9) 1 (2) 0 0 0 
1997 37 30 (81) 3 (8) 0 0 1 (3) 0 
TMP-SMZ = trimethoprim-sulfamethoxszoie. 
DISCUSSION 
The 23-valent vaccine available since 1983 is recom- 
mended for persons aged 65 years of age or older and for 
persons between 2 and 64 years of age who have chronic 
illness with an increased risk for severe pneumococcal 
disease, for example, asplenic patients and those with 
sickle cell disease, cardiac or pulmonary chronic diseases, 
diabetes mellitus, malignancies, organ or bone marrow 
transplantation, HIV or acquired immunodeficiency syn- 
drome (AIDS). l6 
The U.S.Advisory Committee on Immunization Prac- 
tices (ACIP) and committees from other countries,17,‘* 
including Uruguay, recommend vaccination of persons at 
increased risk for severe morbidity and mortality associ- 
ated with pneumococcal disease. However, immunization 
programs in adults have not been as succesful as 
expected.’ 
The present study suggests that the additional risk of 
certain underlying conditions should be considered. In this 
series 27% of cases occurred in patients between 25 and 
65 years of age. It is advisable to evaluate individual risks 
before offering vaccination to patients.19 Likewise, when 
elective splenectomy is being planned, pneumococcal vac- 
cine should be administered at least 2 weeks before surgery 
with revaccination 3 years after the first dose.” 
The immunogenicity of pneumococcal vaccines can 
be evaluated by serologic studies of antibody response, 
indicated by a twofold or greater rise in serotype-specific 
antibodies, developed within 2 to 3 weeks after vacci- 
nation.21J2 Efficacy can be estimated by the decrease of 
pneumococcal invasive diseases and by closely monitor- 
ing the types of isolates involved in disease occurring 
either in vaccinated people or in unprotected individu- 
als. It is important to survey the susceptibility to first line 
antibiotics, to support the empirical management of 
patients, and to verify if all resistant types are included 
in the vaccine formulas.To date, it is noteworthy that all 
p-lactam-resistant isolates detected in our study belonged 
to serotypes represented in the 23-valent vaccine. During 
the 1993-97 period, a progressive increase in the per- 
centages of resistance to penicillin among isolates from 
children under 5 years of age was described.15 The 
1987-1992 studiesz3 demonstrated a low frequency of 
resistance (6%), but in 1994 penicillin resistance increased 
to 29%, reaching 40% in 1996,15 whereas resistance to 
penicillin among invasive isolates from older children 
and adults remained lower (10%). 
These notable differences were probably attributable 
to the introduction and dissemination among the youngest 
group of a clone serotype 14 resistant to penicillin and to 
TMP-SMZ.‘* Serotype 14 isolates resistant to penicillin, 
although predominant in the study population younger 
than 5 years, also was identified in some adults. Molecular 
techniques were used to demonstrate that these belonged 
to the same clone (Camou T. Personal communication). 
Results indicate that because of the baseline pro- 
vided by this study it is possible to certify that 97% of the 
serotypes involved in severe pneumococcal diseases were 
included in the 23-valent vaccine. If these epidemiologic 
data are taken into account for the application of the 
new protein polysaccharide conjugate vaccines, it is note- 
worthy that the most frequently isolated serotypes in the 
surveillance population, serotypes 1 and 5, are included 
in only two of those vaccines, and type 7F is represented 
in only one of those vaccines.25,26 Therefore additional 
epidemiologic studies are mandatory to predict the poten- 
tial success of the vaccines and, after the vaccine appli- 
cation, to detect changes in S. pneumoniae serotype 
prevalence or in susceptibility patterns. 
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